{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,3]],"date-time":"2026-06-03T05:13:21Z","timestamp":1780463601747,"version":"3.54.1"},"reference-count":29,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007824","name":"Soochow University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007824","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002402","name":"Sun Yat-sen University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100002402","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100010854","name":"Jiangsu Provincial Health Commission","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100010854","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biochemical Pharmacology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.bcp.2025.117410","type":"journal-article","created":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T17:22:07Z","timestamp":1760030527000},"page":"117410","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"P4","title":["HKI-357 inhibits castration-resistant prostate cancer by targeting UBE2C via the AKT signaling pathway"],"prefix":"10.1016","volume":"242","author":[{"given":"Li","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenjun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jia","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongze","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangbo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0004-4159-9758","authenticated-orcid":false,"given":"Xue","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.bcp.2025.117410_b0005","doi-asserted-by":"crossref","first-page":"1904","DOI":"10.1002\/cncr.35347","article-title":"Cancer statistics 2024: deaths drop, incidences increase, prevention needed","volume":"130","author":"Nierengarten","year":"2024","journal-title":"Cancer"},{"key":"10.1016\/j.bcp.2025.117410_b0010","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J. Clin."},{"key":"10.1016\/j.bcp.2025.117410_b0015","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41585-021-00442-8","article-title":"Epidemiology and genomics of prostate cancer in asian men","volume":"18","author":"Zhu","year":"2021","journal-title":"Nat. Rev. Urol."},{"key":"10.1016\/j.bcp.2025.117410_b0020","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.6004\/jnccn.2023.0050","article-title":"Prostate cancer, version 4.2023, NCCN clinical practice guidelines in oncology","volume":"21","author":"Schaeffer","year":"2023","journal-title":"J. Natl. Compr. Canc. Netw."},{"key":"10.1016\/j.bcp.2025.117410_b0025","doi-asserted-by":"crossref","first-page":"1947","DOI":"10.1158\/0008-5472.CAN-23-1954","article-title":"m6A modification promotes EMT and metastasis of castration-resistant prostate cancer by upregulating NFIB","volume":"84","author":"Shu","year":"2024","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117410_b0030","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1016\/j.biocel.2013.11.023","article-title":"Ubiquitin-conjugating enzyme E2C: a potential cancer biomarker","volume":"47","author":"Xie","year":"2014","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"10.1016\/j.bcp.2025.117410_b0035","first-page":"4167","article-title":"UbcH10 is the cancer-related E2 ubiquitin-conjugating enzyme","volume":"63","author":"Okamoto","year":"2003","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117410_b0040","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000017896","article-title":"The expression of ubiquitin-conjugating enzyme E2C and KAI1 in ovarian carcinoma and their clinical significance","volume":"98","author":"Gong","year":"2019","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.bcp.2025.117410_b0045","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1007\/s13277-011-0291-1","article-title":"Ubiquitin-conjugating enzyme UBE2C: molecular biology, role in tumorigenesis, and potential as a biomarker","volume":"33","author":"Hao","year":"2012","journal-title":"Tumour Biol."},{"key":"10.1016\/j.bcp.2025.117410_b0050","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1002\/ijc.22605","article-title":"Identification of overexpressed genes in hepatocellular carcinoma, with special reference to ubiquitin-conjugating enzyme E2C gene expression","volume":"121","author":"Ieta","year":"2007","journal-title":"Int. J. Cancer"},{"key":"10.1016\/j.bcp.2025.117410_b0055","doi-asserted-by":"crossref","first-page":"15792","DOI":"10.3390\/ijms242115792","article-title":"Role of UBE2C in brain cancer invasion and dissemination","volume":"24","author":"Domentean","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117410_b0060","doi-asserted-by":"crossref","first-page":"2109","DOI":"10.1016\/j.ajpath.2011.01.034","article-title":"Bortezomib stabilizes mitotic cyclins and prevents cell cycle progression via inhibition of UBE2C in colorectal carcinoma","volume":"178","author":"Bavi","year":"2011","journal-title":"Am. J. Pathol."},{"key":"10.1016\/j.bcp.2025.117410_b0065","doi-asserted-by":"crossref","first-page":"13873","DOI":"10.3390\/ijms232213873","article-title":"Overexpression of ubiquitin-conjugating enzyme E2C is associated with worsened prognosis in prostate cancer","volume":"23","author":"Wu","year":"2022","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.bcp.2025.117410_b0070","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.phrs.2018.11.014","article-title":"Small molecule inhibitors targeting the EGFR\/ErbB family of protein-tyrosine kinases in human cancers","volume":"139","author":"Jr Roskoski","year":"2019","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.bcp.2025.117410_b0075","doi-asserted-by":"crossref","first-page":"4866","DOI":"10.1158\/0008-5472.CAN-10-4576","article-title":"CCI-779 inhibits cell-cycle G2-M progression and invasion of castration-resistant prostate cancer via attenuation of UBE2C transcription and mRNA stability","volume":"71","author":"Wang","year":"2011","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117410_b0080","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1158\/0008-5472.CAN-11-3892","article-title":"Distinct transcriptional programs mediated by the ligand-dependent full-length androgen receptor and its splice variants in castration-resistant prostate cancer","volume":"72","author":"Hu","year":"2012","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117410_b0085","doi-asserted-by":"crossref","first-page":"7665","DOI":"10.1073\/pnas.0502860102","article-title":"Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib","volume":"102","author":"Kwak","year":"2005","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"10.1016\/j.bcp.2025.117410_b0090","doi-asserted-by":"crossref","first-page":"3958","DOI":"10.1158\/0008-5472.CAN-03-2868","article-title":"Antitumor activity of HKI-272, an orally active, irreversible inhibitor of the HER-2 tyrosine kinase","volume":"64","author":"Rabindran","year":"2004","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117410_b0095","doi-asserted-by":"crossref","first-page":"1705","DOI":"10.1080\/15384101.2017.1356507","article-title":"Forkhead Box M1 positively regulates UBE2C and protects glioma cells from autophagic death","volume":"16","author":"Guo","year":"2017","journal-title":"Cell Cycle"},{"key":"10.1016\/j.bcp.2025.117410_b0100","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s13578-021-00555-y","article-title":"DNA primase subunit 1 deteriorated progression of hepatocellular carcinoma by activating AKT\/mTOR signaling and UBE2C-mediated P53 ubiquitination","volume":"11","author":"Zhu","year":"2021","journal-title":"Cell Biosci."},{"key":"10.1016\/j.bcp.2025.117410_b0105","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/s12951-023-02219-0","article-title":"Prostate cancer-derived small extracellular vesicle proteins: the hope in diagnosis, prognosis, and therapeutics","volume":"21","author":"Chen","year":"2023","journal-title":"J. Nanobiotechnol."},{"key":"10.1016\/j.bcp.2025.117410_b0110","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.3390\/biom11091383","article-title":"PAQR6 upregulation is associated with AR signaling and unfavorite prognosis in prostate cancers","volume":"11","author":"Yang","year":"2021","journal-title":"Biomolecules"},{"key":"10.1016\/j.bcp.2025.117410_b0115","doi-asserted-by":"crossref","first-page":"849","DOI":"10.1158\/2159-8290.CD-12-0460","article-title":"Molecular classification of prostate cancer progression: foundation for marker-driven treatment of prostate cancer","volume":"3","author":"Logothetis","year":"2013","journal-title":"Cancer Discov."},{"key":"10.1016\/j.bcp.2025.117410_b0120","article-title":"Prostate cancer immunotherapy: improving clinical outcomes with a multi-pronged approach","volume":"4","author":"Sridaran","year":"2023","journal-title":"Cell Rep. Med."},{"key":"10.1016\/j.bcp.2025.117410_b0125","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1016\/j.juro.2018.07.090","article-title":"Castration-resistant prostate cancer: AUA guideline amendment 2018","volume":"200","author":"Lowrance","year":"2018","journal-title":"J. Urol."},{"key":"10.1016\/j.bcp.2025.117410_b0130","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/1756-8722-4-18","article-title":"Progression of metastatic castrate-resistant prostate cancer: impact of therapeutic intervention in the post-docetaxel space","volume":"4","author":"Sartor","year":"2011","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.bcp.2025.117410_b0135","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1158\/0008-5472.CAN-18-2738","article-title":"AKT as a therapeutic target for cancer","volume":"79","author":"Song","year":"2019","journal-title":"Cancer Res."},{"key":"10.1016\/j.bcp.2025.117410_b0140","doi-asserted-by":"crossref","first-page":"62","DOI":"10.1158\/1541-7786.MCR-21-0108","article-title":"GLI3 is stabilized by SPOP Mutations and promotes castration resistance via functional cooperation with androgen receptor in prostate cancer","volume":"20","author":"Burleson","year":"2022","journal-title":"Mol. Cancer Res."},{"key":"10.1016\/j.bcp.2025.117410_b0145","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1038\/emboj.2011.154","article-title":"Phospho-MED1-enhanced UBE2C locus looping drives castration-resistant prostate cancer growth","volume":"30","author":"Chen","year":"2011","journal-title":"EMBO J."}],"container-title":["Biochemical Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006756?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0006295225006756?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,1,27]],"date-time":"2026-01-27T01:35:12Z","timestamp":1769477712000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0006295225006756"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":29,"alternative-id":["S0006295225006756"],"URL":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117410","relation":{},"ISSN":["0006-2952"],"issn-type":[{"value":"0006-2952","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"HKI-357 inhibits castration-resistant prostate cancer by targeting UBE2C via the AKT signaling pathway","name":"articletitle","label":"Article Title"},{"value":"Biochemical Pharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bcp.2025.117410","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117410"}}